The Manila Times

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech, Inc. (Nasdaq: FBIO) ('Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ('Cyprium”), ...